GLSI Greenwich LifeSciences, Inc.
Distress ·
Greenwich LifeSciences said on March 31, 2026 that its annual report for 2025 would be late. Its 2024 annual report already carried an auditor's going concern paragraph, with $4,091,990 in cash at year end against a $15,788,809 net loss.
The company filed a late-filing notice for its quarterly report for the three months ended March 31, 2025. Its lead candidate, GLSI-100, is in a Phase III trial that is still expanding.
The company says it cannot file its 2024 annual report on time and expects to use the 15-day extension. Research and development expenses rose to $12,952,029, and the Phase IIb data behind its lead trial carry unresolved record gaps.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $17.2 million | $15.5 million |
| Net income (loss) | -$19.4 million | -$17.4 million |
| Cash from operations | -$9.9 million | -$7.3 million |
| Cash and equivalents | $6.2 million | $4.1 million |
Our latest story on this, dated Mar 31, 2026: "Greenwich LifeSciences, Inc. files NT 10-K, says annual report will be late". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 15, 2025: "Greenwich LifeSciences delays first-quarter report, expects to file by May 20, 2025". The story links the filing or release it is based on. Read the story.
Greenwich LifeSciences, Inc. trades under the ticker GLSI on NASDAQ.
Greenwich LifeSciences, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Greenwich LifeSciences, Inc. is 1799788. Its filings are on SEC EDGAR.
14,678,208 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Greenwich LifeSciences, Inc. under United States.
Our directory classifies Greenwich LifeSciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Greenwich LifeSciences, Inc. is US3968791083.
aibio.space lists Greenwich LifeSciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Greenwich LifeSciences, Inc. reported a net loss of $19.4 million for the fiscal year ended Dec 31, 2025, and used $9.9 million of cash in operations, per its annual report to the SEC.
$17.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$8.9 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Greenwich LifeSciences, dated Mar 31, 2026: "Greenwich LifeSciences, Inc. files NT 10-K, says annual report will be late". Greenwich LifeSciences said on March 31, 2026 that its annual report for 2025 would be late. Its 2024 annual report already carried an auditor's going concern paragraph, with $4,091,990 in cash at year end against a $15,788,809 net loss. Source.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio